2025-04-19 - Analysis Report
## Intuitive Surgical Inc. (ISRG) Stock Report

This report analyzes Intuitive Surgical Inc., a company that manufactures and sells robotic-assisted surgical systems.

**1) Performance Comparison & Alpha/Beta Analysis:**

ISRG's cumulative return (109.17%) significantly outperforms the S&P 500 (VOO) cumulative return (76.18%) by 33.0 percentage points.  The relative divergence (37.3%) indicates ISRG's performance is above the average historical difference compared to the S&P 500, placing it in the upper range of historical performance relative to the index.

The Alpha/Beta analysis reveals a generally positive alpha (outperformance relative to the market) in recent years, except for 2020-2023.  The beta, measuring volatility relative to the market, increased over the analyzed period. The market capitalization (Cap(B)) consistently increased.


| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 68.0% | 56.5% | 35.0% | -0.0 | 43.6 |
| 2016-2018  | 77.0% | 63.4% | 56.0% | -0.1 | 57.2 |
| 2017-2019  | 81.0% | 63.4% | 47.0% | 0.4 | 70.6 |
| 2018-2020  | 47.0% | 63.4% | 17.0% | 0.4 | 97.7 |
| 2019-2021  | 91.0% | 63.0% | 31.0% | 0.4 | 128.7 |
| 2020-2022  | -3.0% | 69.9% | -12.0% | 0.5 | 95.1 |
| 2021-2023  | -5.0% | 72.9% | -26.0% | 1.1 | 120.9 |
| 2022-2024  | 26.0% | 72.9% | 5.0% | 1.1 | 187.0 |
| 2023-2025  | 30.0% | 72.9% | 15.0% | 0.7 | 172.9 |


**2) Recent Price Movement:**

The closing price is $482.74.  The stock price shows a slight upward trend recently, although it's below its 5-day, 20-day, and 60-day moving averages.

* Closing Price: $482.74
* 5-Day Moving Average: $487.22
* 20-Day Moving Average: $492.22
* 60-Day Moving Average: $537.09

**3) Technical Indicators & Expected Return:**

The RSI (47.78) suggests the stock is neither overbought nor oversold. The PPO (0.39) indicates a potential bullish trend. The recent relative divergence change (-0.9) shows a short-term downward trend.  The market risk indicator (MRI) of 0.42 suggests a low to medium risk profile.  The 0.29 daily change is relatively small and doesn't indicate a significant jump or drop.  The expected return of 47.1% over the long term (2+ years) represents a significant outperformance compared to the S&P 500.

**4) Recent Earnings Analysis:**

Revenue and EPS have shown a generally upward trend, though there's some fluctuation quarter-to-quarter.  The duplicate entry for October 18th, 2024 needs clarification.

| Date       | EPS  | Revenue       |
|------------|------|---------------|
| 2024-10-18 | 1.59 | $2.04B         |
| 2024-07-19 | 1.48 | $2.01B         |
| 2024-04-19 | 1.54 | $1.89B         |
| 2023-10-20 | 1.18 | $1.74B         |
| 2024-10-18 | 1.18 | $1.74B         |


**5) Financial Information:**

Revenue shows a generally upward trend. Profit margins are consistently high, indicating strong profitability. Equity has also increased steadily. ROE fluctuates, suggesting variations in profitability relative to equity.  Further analysis is needed to understand the causes of these fluctuations.


Revenue and Profitability:

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2024-12-31 | $2.41B | 68.04% |
| 2024-09-30 | $2.04B | 67.41% |
| 2024-06-30 | $2.01B | 68.30% |
| 2024-03-31 | $1.89B | 65.87% |
| 2023-12-31 | $1.93B | 66.24% |

Capital and Profitability:

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2024-12-31 | $16.43B | 4.17% |
| 2024-09-30 | $15.58B | 3.63% |
| 2024-06-30 | $14.71B | 3.58% |
| 2024-03-31 | $13.96B | 3.90% |
| 2023-12-31 | $13.31B | 4.56% |


**6) Overall Summary:**

ISRG has shown strong historical performance significantly outperforming the S&P 500.  While recent price action shows a slight downward trend, technical indicators suggest neither overbought nor oversold conditions.  Consistent high profit margins and increasing revenue demonstrate financial strength.  However, the recent slight downturn and the fluctuation in ROE warrant further investigation. The long-term outlook, based on expected returns, remains positive, but investors should monitor the stock closely for any significant changes in the market or the company's financial performance.  The duplicate earnings data entry requires clarification.  A deeper dive into the company's specific drivers of growth and potential risks is recommended before making investment decisions.
